MicroCoal(tm) Appoints James Young, PhD, Past President of R&D

FSC / Press Release 
MicroCoal(tm) Appoints James Young, PhD, Past President of R&D for MedImmune
Inc., as Chairman of the Board 
Vancouver, British Columbia CANADA, September 06, 2013 /FSC/ - MicroCoal
Technologies Inc. (MTI - CNSX, CFQSF - OTC Pink),("the "Company" or
"MicroCoal"), is pleased to announce that it has appointed Dr. James Young as
Chairman of the Board of Directors. 
Holding a Ph.D. in Microbiology and Immunology from Baylor College of Medicine,
Dr. Young currently serves as chairman of the Board of Directors of Novavax,
Inc. (NASDAQ:NVAX) and is on the Board of Directors for 3-V Biosciences, Inc., a
private drug company. Young was with MedImmune, Inc. from 1988 through 2008
following its sale to AstraZeneca PLC in 2007. During his entire tenure, Dr.
Young led MedImmune's research and development organization and was directly
involved in the development of approximately twenty clinical programs and
commercialization of Synagis(r), RespiGam(r), CytoGam(r), Flumist(r), and
Ethyol(r). At the time of his retirement from MedImmune, Dr. Young oversaw R&D
functions including approximately 1,500 people and an annual budget in excess of
$700 million. Prior to MedImmune, Dr. Young was a Director in the Department of
Molecular Genetics at Smith Kline and French Laboratories, now part of
GlaxoSmithKline. Dr. Young has served on the Boards of Directors of Xencor,
Inc., Iomai, Inc. and Arriva Pharmaceuticals, Inc. 
Synagis(r), RespiGam(r), CytoGam(r), Flumist(r), and Ethyol(r) are registered
trademarks of MedImmune, LLC, an AstraZeneca PLC company. 
Slawek Smulewicz, CEO and Director of the Company, reports: "We are very pleased
to welcome Dr. Young to the MicroCoal(tm) Board," "James' expertise as a
scientist, track record of accessing government funding, and building successful
companies makes him exceptionally well suited to advance the Company in its
mission to build MicroCoal(tm) as the leading clean coal company. From having
been head of research and development at MedImmune, Inc., since its founding in
1989 until 2008 following its sales to AstraZeneca for $15.6 billion, James has
the experience and wisdom to build a world-class company. 
Lastly, I would like to take this opportunity to thank William Hudson for
serving as Chairman of the Board for the last three (3) years and look forward
to working with him as a Director as we now move forward to the next phase of
MicroCoal(tm)'s evolution." 
Upon appointment as Chairman of the Board of Directors, Dr. Young stated: "I'm
very excited by the potential for MicroCoal(tm)'s highly innovative microwave
technology to dry coal. This approach has the potential to improve the thermal
output of coal and reduce the pollution it generates and therefore be an
important part of a worldwide energy solution.  The recent announcement of the
first commercial installation of the technology by PT Wijaya Tri Utama in
Indonesia will serve to showcase the scalability of this modular microwave coal
drying technology, which can be applied to coal-fired power plants worldwide.
This marks the global commercial roll-out for this revolutionary technology. 
Further, I am happy to be participating in the Company's private placement
announced yesterday and I look forward to working with management to build the
finest clean coal company in the world." 
William Hudson, who has served as Chairman of the Board for the past 3 years
stated: "I am pleased to have nominated Dr. Young to succeed as Chairman of the
Board.  He brings vision, vitality, and expertise to the Company.  We all see
this as a positive step advancing the success of the company and adding value
for its shareholders"." 
About MicroCoal(tm) Technologies Inc. 
The Company is focused on commercializing its unique, clean-coal upgrading
technology known as MicroCoal(tm); a low-cost, patented microwave technology
that reduces moisture in coal resulting in an upgraded energy content of coal.
This process provides significant financial benefits to coal-fired electrical
generating utilities such as: large cost savings from switching to low-rank
coal, substantial increases in boiler efficiencies and heat output, improved ash
efficiencies and reductions in scrubber costs. Important environmental benefits
including reductions in most greenhouse gases (SOx up to 70%, NOx up to 50%, CO2
up to 17%) and mercury are also key primary benefits from implementation of this
technology. The Company is currently constructing the first commercial facility
in Indonesia with other projects soon to be announced. 
We seek safe harbor. 
On behalf of the Board of Directors, 
"Slawek Smulewicz"
CEO and Director 
For further information please contact: 
Malcolm Bell
MicroCoal(tm) Technologies Inc.
Telephone: (604) 676 9792
E-mail: info@microcoal.com 
Certain statements included herein, including those that express management's
expectations or estimates of our future performance constitute "forward-looking
statements" within the meaning of applicable securities laws. Forward-looking
statements are necessarily based upon a number of estimates and assumptions
that, while considered reasonable by management at this time, are inherently
subject to significant business, economic and competitive uncertainties and
contingencies. Investors are cautioned not to put undue reliance on forward
looking statements. Except as required by law, the Corporation does not intend,
and undertakes no obligation, to update any forward-looking statements to
reflect, in particular, new information or future events. Neither CNSX nor its
Regulation Services Provider (as that term is defined in the policies of the
CNSX) accepts responsibility for the adequacy or accuracy of the release. 
To view this press release as a PDF, please click on the following link:
Source: MicroCoal Technologies Inc. (CNSX: MTI) http://www.microcoal.com
Maximum News Dissemination by FSCwire. http://www.fscwire.com 
Provider ID: 00022173
-0- Sep/06/2013  9:00 GMT
Press spacebar to pause and continue. Press esc to stop.